Lyell Immunopharma, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 0.013 million compared to USD 48.39 million a year ago. Net loss was USD 52.93 million compared to USD 8.4 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.17 USD | -1.36% | -2.69% | +11.86% |
Mar. 04 | North American Morning Briefing : Stock Futures -2- | DJ |
Feb. 28 | Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.86% | 553M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- LYEL Stock
- News Lyell Immunopharma, Inc.
- Lyell Immunopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023